Douglas Fambrough, a principal at Boston-based Oxford Bioscience Partners, has been appointed to the audit committee of Solexa.
Fambrough currently sits on the board of Sirna Therapeutics. He holds a PhD in genetics from the University of California, Berkeley.
Pharmacyclics said that board member Loretta Itri will not stand for re-election at the company’s annual meeting in December.
According to the firm, she is leaving the board in order to focus on her duties as president and chief medical officer of Genta.